A Japanese flu drug gets upbeat reviews in China for blunting the impact of Covid-19 — and that is bolstering Gilead's case for remdesivir
We’re starting to get the first round of data on drugs being used to rein in the devastating outbreak of Covid-19 in China. And one drug from Japan is getting a thumbs-up based on a pair of small trials being used as pivotals in the crisis — which appear to open the way to widespread use.
That new readout has already attracted the attention of one Wall Street analyst, who sees a direct read-through to Gilead’s remdesivir, where data on the coronavirus are expected in weeks.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 76,800+ biopharma pros reading Endpoints daily — and it's free.